Amgen Slides After Guidance; Q4 Beat, Insider Sale

Introduction

Amgen (AMGN) delivered a mixed message this quarter: robust Q4 results and bullish pipeline developments were offset by cautious 2026 guidance, an executive insider sale, and operational signs that spooked investors. Over the past week the stock moved sharply—reaching an all-time high in late February before falling after the guidance and other disclosures in early March. This article breaks down the facts, quantifies the impacts, and highlights the catalysts investors should watch closely.

What Happened Last Week

Q4 results beat expectations

On February 3, Amgen reported fourth-quarter revenue of approximately $9.9 billion and adjusted EPS of about $5.29—results that topped consensus estimates. Management reiterated confidence in key pipeline assets, including the experimental weight-loss candidate MariTide, which helped drive bullish analyst commentary and pushed the stock briefly to new highs.

Stock hit a new high, then reversed

In late February, the combination of better-than-expected earnings and positive pipeline commentary sent AMGN to an all-time intraday peak near $385.63, producing a one-year gain of roughly 25% and a six-month rally of some 35% for holders. That momentum proved fragile once guidance and other disclosures landed.

Guidance, inventory, and insider activity sparked the sell-off

Early March brought more nuanced guidance and operational disclosures. Management issued 2026 revenue guidance that implied slower growth—around 1.9% versus a prior roughly 3% pace—that disappointed some investors expecting stronger near-term acceleration. Additionally, Amgen disclosed a roughly $250 million inventory build in Q4, a detail that often presages weaker near-term shipments and can weigh on next-quarter revenue.

Compounding those concerns, a senior executive executed a roughly $20.8 million insider sale, which drew attention and likely added to short-term selling pressure. On March 3 the stock slid about 2.26%, and by March 5 it fell an additional ~3.08% amid elevated trading volumes.

Key Data Points Investors Should Know

• Reported Q4 revenue: ~ $9.9 billion
• Adjusted Q4 EPS: ~ $5.29
• 2026 revenue guidance range: approximately $37.0B to $38.4B
• Inventory build reported: ~ $250 million
• Insider sale reported: ~ $20.77 million
• Stock peak in late February: ~$385.63
• Recent intraday declines: ~ -2.26% (Mar 3) and ~ -3.08% (Mar 5)

Regulatory and product-level pressure

Beyond the headline numbers, Amgen also faces product-specific challenges. Biosimilar competition and pricing pressure remain risks for legacy products such as Enbrel, Prolia and Xgeva. Reports of Medicare pricing uncertainty and ongoing scrutiny around select drugs—such as FDA attention toward Tavneos—add another layer of revenue and margin sensitivity.

What This Means for AMGN Stock

The recent price action reflects a classic investor shift from momentum to scrutiny: strong execution and pipeline optimism lifted the stock, but conservative guidance, operational noise (inventory builds), and insider selling introduced tangible short-term risks. For longer-term investors, the core thesis—stable cash flows from established biologics combined with growth upside from new launches—remains intact, but timing and near-term earnings volatility have increased.

Short-term outlook

Expect volatility around quarterly reports, guidance updates, and any clinical readouts for high-profile assets like MariTide. Near-term headwinds include biosimilar erosion, inventory adjustments, and payer negotiations that could compress realized prices.

Long-term view

If Amgen advances its late-stage candidates and successfully mitigates pricing pressures on key biologics, the company can still deliver steady earnings growth. The recent pullback may create an entry point for investors focused on long-term fundamentals, but disciplined monitoring of guidance and regulatory signals is essential.

Conclusion

Last week’s activity in AMGN reflected a tension between strong operational results and conservative near-term messaging. Q4 beat and a robust pipeline drove optimism, but slower guidance, a notable inventory build and an executive insider sale prompted short-term selling. Investors should prioritize upcoming pipeline milestones, guidance clarity, and payer/regulatory developments when assessing Amgen’s direction. These are the concrete drivers most likely to move the stock in the coming quarters.